特集 : 国別レポートが13,000件から検索可能になりました!

特集 : 海外市場の委託調査がセミカスタムベースでお手軽にできます

株式会社グローバルインフォメーション
表紙
市場調査レポート
商品コード
229726

腎臓癌:パイプライン分析

Kidney Cancer (Renal Cell Cancer) - Pipeline Review, H1 2020

出版日: | 発行: Global Markets Direct | ページ情報: 英文 2815 Pages | 納期: 即納可能 即納可能とは

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=105.49円
腎臓癌:パイプライン分析
出版日: 2020年06月30日
発行: Global Markets Direct
ページ情報: 英文 2815 Pages
納期: 即納可能 即納可能とは
担当者のコメント
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 図表
  • 目次
概要

腎臓癌は、腎臓細胞が悪性となって癌になり、制御ができなくなり腫瘍を作り出す疾患です。症状には血尿、食欲不振、何週間も続く熱、ひどい疲労感、貧血、息切れ、骨痛などが見られます。治療法としては外科手術、放射線治療、化学療法などがあります。

当レポートでは、腎臓癌の治療薬開発パイプラインの現況と最新アップデートによる各開発段階の比較分析、企業や研究機関によって開発中の治療薬、治療薬の評価、後期段階および中止されたプロジェクトに関する情報などを最新のニュースや発表も交えて提供しています。

イントロダクション

  • 腎臓癌 概要

治療薬の開発

企業で開発中の治療薬

大学/機関で研究中の治療薬

パイプライン製品の概況

企業で開発中の製品

大学/機関で研究中の製品

治療薬開発に従事している企業

治療薬の評価

薬剤プロファイル

最近のパイプライン動向

休止中のプロジェクト

開発が中止された製品

製品開発のマイルストーン

付録

図表

List of Tables

List of Tables

  • Number of Products under Development for Kidney Cancer (Renal Cell Cancer), H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products under Development by Universities/Institutes, H1 2020
  • Number of Products under Development by Universities/Institutes, H1 2020 (Contd..1), H1 2020
  • Products under Development by Companies, H1 2020
  • Products under Development by Universities/Institutes, H1 2020
  • Number of Products by Stage and Target, H1 2020
  • Number of Products by Stage and Mechanism of Action, H1 2020
  • Number of Products by Stage and Route of Administration, H1 2020
  • Number of Products by Stage and Molecule Type, H1 2020
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by 4D Pharma Plc, H1 2020
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by 4SC AG, H1 2020
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by Aadi Bioscience Inc, H1 2020
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by AbbVie Inc, H1 2020
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by ABL Bio Inc, H1 2020
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by Acepodia Biotech Inc, H1 2020
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by Acrotech Biopharma LLC, H1 2020
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by Actuate Therapeutics Inc, H1 2020
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by Adaptimmune Therapeutics Plc, H1 2020
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by ADC Therapeutics SA, H1 2020
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by Adlai Nortye Biopharma Co Ltd, H1 2020
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by Advenchen Laboratories LLC, H1 2020
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by Affimed GmbH, H1 2020
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by Affitech A/S, H1 2020
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by Agenus Inc, H1 2020
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by AIM ImmunoTech Inc, H1 2020
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by Akeso Inc, H1 2020
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by Alkermes Plc, H1 2020
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by Alligator Bioscience AB, H1 2020

List of Figures

List of Figures

  • Number of Products under Development for Kidney Cancer (Renal Cell Cancer), H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products under Development by Universities/Institutes, H1 2020
  • Number of Products by Top 10 Targets, H1 2020
  • Number of Products by Stage and Top 10 Targets, H1 2020
  • Number of Products by Top 10 Mechanism of Actions, H1 2020
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
  • Number of Products by Top 10 Routes of Administration, H1 2020
  • Number of Products by Stage and Top 10 Routes of Administration, H1 2020
  • Number of Products by Top 10 Molecule Types, H1 2020
  • Number of Products by Stage and Top 10 Molecule Types, H1 2020
目次
Product Code: GMDHC12344IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Kidney Cancer - Pipeline Review, H1 2020, provides an overview of the Kidney Cancer (Oncology) pipeline landscape.

Kidney cancer also called renal cancer is a disease in which kidney cells become malignant (cancerous) and grows out of control, forming a tumor. Symptoms include blood in urine, loss of appetite, fever that lasts for weeks, extreme fatigue, and anemia, shortness of breath and bone pain. Treatment includes surgery, radiation therapy and chemotherapy.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Kidney Cancer - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Kidney Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Kidney Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Kidney Cancer (Renal Cell Cancer) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 4, 1, 20, 162, 156, 2, 12, 101, 11 and 3 respectively. Similarly, the Universities portfolio in Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages comprises 14, 8, 1, 16 and 1 molecules, respectively.

Kidney Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Kidney Cancer (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Kidney Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Kidney Cancer (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Kidney Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Kidney Cancer (Oncology)

Reasons to Buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Kidney Cancer (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Kidney Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

Table of Contents

  • Introduction
  • Kidney Cancer - Overview
  • Kidney Cancer - Therapeutics Development
  • Kidney Cancer - Therapeutics Assessment
  • Kidney Cancer - Companies Involved in Therapeutics Development
  • Kidney Cancer - Drug Profiles
  • Kidney Cancer - Dormant Projects
  • Kidney Cancer - Discontinued Products
  • Kidney Cancer - Product Development Milestones
  • Appendix
株式会社グローバルインフォメーション
© Copyright 1996-2020, Global Information, Inc. All rights reserved.